EA201991305A1 - Производные тирозина и композиции, включающие их - Google Patents

Производные тирозина и композиции, включающие их

Info

Publication number
EA201991305A1
EA201991305A1 EA201991305A EA201991305A EA201991305A1 EA 201991305 A1 EA201991305 A1 EA 201991305A1 EA 201991305 A EA201991305 A EA 201991305A EA 201991305 A EA201991305 A EA 201991305A EA 201991305 A1 EA201991305 A1 EA 201991305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tyrosine hydroxylase
compositions including
hydroxylase inhibitor
tyrosine derivatives
including theirs
Prior art date
Application number
EA201991305A
Other languages
English (en)
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed filed Critical
Publication of EA201991305A1 publication Critical patent/EA201991305A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201991305A 2016-11-30 2017-11-30 Производные тирозина и композиции, включающие их EA201991305A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
EA201991305A1 true EA201991305A1 (ru) 2019-10-31

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991305A EA201991305A1 (ru) 2016-11-30 2017-11-30 Производные тирозина и композиции, включающие их

Country Status (12)

Country Link
EP (1) EP3548086A1 (enExample)
JP (2) JP2019536783A (enExample)
KR (1) KR20190089191A (enExample)
CN (1) CN110062633A (enExample)
AU (1) AU2017368135A1 (enExample)
BR (1) BR112019011033A2 (enExample)
CA (1) CA3045110A1 (enExample)
EA (1) EA201991305A1 (enExample)
IL (1) IL266840A (enExample)
MX (1) MX2019006326A (enExample)
PH (1) PH12019501186A1 (enExample)
WO (1) WO2018102506A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
WO2021090069A1 (en) * 2019-11-07 2021-05-14 In3Bio Ltd. Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
EP4090329A2 (en) * 2020-01-17 2022-11-23 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP1718145A4 (en) * 2004-02-02 2012-03-07 Biosight Ltd CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
WO2007120153A1 (en) * 2006-04-19 2007-10-25 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
HUE027443T2 (en) * 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
KR102172658B1 (ko) * 2012-01-17 2020-11-02 타임, 인크. 약학 조성물 및 방법
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
AU2017368135A1 (en) 2019-06-13
CA3045110A1 (en) 2018-06-07
KR20190089191A (ko) 2019-07-30
MX2019006326A (es) 2019-07-12
CN110062633A (zh) 2019-07-26
WO2018102506A1 (en) 2018-06-07
IL266840A (en) 2019-07-31
BR112019011033A2 (pt) 2019-10-15
EP3548086A1 (en) 2019-10-09
JP2022153587A (ja) 2022-10-12
JP2019536783A (ja) 2019-12-19
PH12019501186A1 (en) 2020-02-10

Similar Documents

Publication Publication Date Title
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MY195110A (en) Antibodies to PD-1 and uses Thereof
JOP20200342A1 (ar) مشتقات بيرازين مدمجة كمثبطات a2a/a2b
MX2017013613A (es) Neoepitodos de cancer.
JOP20190285A1 (ar) استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201991305A1 (ru) Производные тирозина и композиции, включающие их
EA201991555A1 (ru) Композиции и способы усиления или увеличения продукции ifn i типа
MX2016011619A (es) Anticuerpos anti-egfrviii y usos de los mismos.
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
BR112015020290A2 (pt) métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
MX374785B (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
JOP20200016B1 (ar) أجسام مضادة لـ cd137
EA201591546A1 (ru) Мультивалентные и моновалентные мультиспецифические комплексы и их применение
CR20110553A (es) Terapia complementaria contra el cáncer
MX387296B (es) Proliferacion ex vivo de celulas epiteliales.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MX2017003627A (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
BR112013006331A2 (pt) composições de fulvestranto e métodos de uso
MX2017003626A (es) Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EP4414035A3 (en) Combined preparations for the treatment of cancer